Current Report Filing (8-k)
April 01 2022 - 6:03AM
Edgar (US Regulatory)
0000316253
false
0000316253
2022-03-31
2022-03-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
March 31, 2022
Enzo Biochem, Inc.
(Exact Name of Registrant as Specified in Its Charter)
New York
(State or Other Jurisdiction of Incorporation)
001-09974 |
|
13-2866202 |
(Commission File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
527 Madison Avenue |
|
|
New York, New York |
|
10022 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(212) 583-0100
(Registrant’s Telephone Number, Including
Area Code)
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of Each Class |
|
Trading Symbol |
|
Name of Each Exchange on Which Registered |
Common Stock, $.01 par value |
|
ENZ |
|
The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-1 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item
5.07 Submission of Matters to a Vote of Security Holders.
On March 31, 2022, Enzo Biochem, Inc. (the “Company”) held
its 2021 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the holders of 43,260,013 (89.24%)
shares of the Company’s common stock entitled to vote were represented in person or by proxy constituting a quorum
At the Annual Meeting, shareholders:
| ● | Elected
Hamid Erfanian and Bradley L. Radoff to (i) serve as the Class I Directors to hold office
for a term of three (3) years or until their successors have been duly elected and qualified,
or (ii) if the shareholders approve Proposal 1(b), to serve on the Company’s board
of directors (the “Board”) for a term ending as of our 2022 annual meeting of
shareholders, and until each such director’s successor is duly elected and qualified
(“Election of Directors”); |
| ● | Approved,
on an advisory basis, the appointment of EisnerAmper LLP as the Company’s independent
auditors for the fiscal year ending July 31, 2022 (“Advisory approval of Auditors”);
and |
| ● | Approved
the non-binding advisory resolution relating to executive compensation (“Advisory approval
of Executive Compensation”). |
The
specific votes were as follows:
|
1. | The Election of Directors: |
VOTES* |
|
FOR | |
AGAINST | |
ABSTAIN |
35,573,284 | |
714,621 | |
812,506 |
|
* | There were 6,159,602 broker non-votes on this matter. |
|
2. | Advisory approval of Executive Compensation. |
VOTES* |
|
FOR | |
AGAINST | |
ABSTAIN |
24,559,237 | |
10,105,380 | |
2,435,794 |
|
* | There were 6,159,602 broker non-votes on this matter. |
|
3. | Advisory approval of Auditors: |
VOTES |
|
FOR | |
AGAINST | |
ABSTAIN |
42,860,170 | |
225,757 | |
174,086 |
In addition, the vote to approve amendments to
the Company’s Certificate of Incorporation, as amended, as indicated in the six sub-proposals below, was adjourned to April 8, 2022
to give the Company additional time to solicit votes in favor of the six sub-proposals. The Annual Meeting will reconvene virtually via
the internet at www.virtualshareholdermeeting.com/ENZ2022 with respect to this proposal on Friday, April 8, 2022 at 9:00 a.m.,
EST.
| (a) | to change the purpose of the Company to carry on any lawful business; |
| (b) | to declassify the Board; |
| (c) | to remove Article 7 regarding the Company’s first accounting period for 1976; |
| (d) | to change the required shareholder vote for approval of mergers, asset sales, and dissolution from two-thirds
vote to majority vote; |
| (e) | to change the required shareholder vote for amendments to the Certificate of Incorporation to a majority
vote; and |
| (f) | to change the required vote for amendments to the Company’s Amended and Restated By-Laws to either
majority board approval or majority shareholder approval. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
ENZO BIOCHEM, INC. |
|
|
|
Date: March 31, 2022 |
By: |
/s/ David Bench |
|
|
David Bench |
|
|
Chief Financial Officer, Senior Vice President, Treasurer, and Corporate Secretary |
2
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024